Abstract
Early monitoring of HCVRNA during interferon treatment may allow clinicians to obtain important information that could help them to adopt therapeutic decisions in individual cases. The hepatitis C virus infection is highly dynamic and a daily high dose of IFN may induce a decline of viremia of 95 ± 10% of baseline value after 24 to 48 hours of treatment. The importance of this early antiviral efficacy has not been understood. We have measured HCVRNA levels in 47 patients with chronic hepatitis C infection during interferon treatment to study HCVRNA kinetics and evaluate the predictive value of the early decay of viremia on the virological response after one month of treatment. Sixty percent of treated patients showed early virological response (EVR) and it was significantly associated with low HCVRNA levels and a genotype other than 1b. Finally, the absence of an 85% decline in HCVRNA levels after 3 days of treatment observed in 11 out of 45 patients (24%) was an absolute and very early predictor of the absence of EVR in the study population. J. Clin. Lab. Anal. 14:120–124, 2000. © 2000 Wiley‐Liss, Inc.
Keywords: HCV, viremia, IFN, response
REFERENCES
- 1. EASL International Consensus Conference on Hepatitis C. J Hepatol 1999;30: 956–961. [PubMed] [Google Scholar]
- 2. Davis GL. Prediction of response to interferon treatment of chronic viral hepatitis. J Hepatol 1994;21:1–3. [DOI] [PubMed] [Google Scholar]
- 3. Tsubota A, Chayama K, Ikeda K, Yasuji A, et al. Factors predictive of response to interferon‐alpha therapy in hepatitis C virus infection. Hepatol 1994;19:1088–1094. [PubMed] [Google Scholar]
- 4. Yoshioka K, Kakumu S, Wakita T, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon‐alpha therapy: relationship to genotypes of HCV. Hepatol 1992;16:293–299. [DOI] [PubMed] [Google Scholar]
- 5. Lam NP, Neuman A, Gretch D, Wiley T, Perelson A, Layden T. Dose‐dependent acute clearance of hepatitis C genotype 1 virus with interferon alpha. Hepatology 1997;26:226–231. [DOI] [PubMed] [Google Scholar]
- 6. Idilman R, De Maria N, Colantoni A, Dokmeci A, Van Thiel DH. Interferon treatment of cirrhosis patients with chronic hepatitis C. J Viral Hepatitis 1997;4:81–91. [DOI] [PubMed] [Google Scholar]
- 7. Gavier B, Martinez‐Gonzalez MA, Riezu‐Boj JI, et al. Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. Gastroenterology 1997;113:1647–1653. [DOI] [PubMed] [Google Scholar]
- 8. Neuman AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon‐alpha therapy. Science 1998;282:103–107. [DOI] [PubMed] [Google Scholar]
- 9. Dusheiko GM, Zuckerman AJ. Treatment of chronic viral hepatitis. J Antimicrob Chemother 1993;32:107–120. [DOI] [PubMed] [Google Scholar]
- 10. Fried MW, Hoofnage JH. Therapy of hepatitis C. Semin Liver Dis 1995;15:82–91. [DOI] [PubMed] [Google Scholar]
- 11. Taylor D, Shi S, Romano P, Barber G, Lai M. Inhibition of the interferon‐inducible protein kinase PKR by HCV E2 protein. Science 1999;285:107–110. [DOI] [PubMed] [Google Scholar]
- 12. Yamamoto C, Enomoto N, Kurosaki M, et al. Nucleotide sequence variations in the Internal Ribosome Entry Site of hepatitis C virus‐1b: no association with efficacy of interferon therapy or serum HCV‐RNA levels. Hepatology 1997;26:1616–1620. [DOI] [PubMed] [Google Scholar]
- 13. Rispeter K, Lu M, Wiese M, et al. The “interferon sensitivity determining region” of hepatitis C virus is a stable sequence element. J Hepatol 1998;29:352–361. [DOI] [PubMed] [Google Scholar]
- 14. Khorsi H, Castelain S, Wyseur A, et al. Mutations of hepatitis C virus 1b NS5S 2209‐2248 amino acid sequence do not predict the response to recombinant interferon‐alpha therapy in French patients. J Hepatol 1997;27:72–77. [DOI] [PubMed] [Google Scholar]
- 15. McHutchison J, Gordon S, Schif E, et al. Interferon alpha‐2 alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485–1492. [DOI] [PubMed] [Google Scholar]
- 16. Davis G, Esteban R, Rustgi V, et al. Interferon alpha‐2a alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493–1499. [DOI] [PubMed] [Google Scholar]